Key terms
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRSN news
Mar 19
4:50am ET
Mersana Therapeutics upgraded to Neutral from Underweight at JPMorgan
Mar 12
8:37am ET
Mersana Therapeutics (MRSN) Gets a Buy from Truist Financial
Mar 01
1:07am ET
Buy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming Milestones
Feb 29
7:48am ET
Wedbush bullish on Mersana Therapeutics, upgrades to Outperform
Feb 29
7:19am ET
Truist Financial upgrades Mersana Therapeutics (MRSN) to a Buy
Feb 29
7:09am ET
Mersana Therapeutics upgraded to Buy from Hold at Truist
Feb 29
6:05am ET
Mersana Therapeutics upgraded to Outperform from Neutral at Wedbush
Feb 29
5:14am ET
Guggenheim upgrades Mersana Therapeutics on XMT-1660 potential
Feb 29
1:03am ET
Bad News for Mersana Therapeutics Stock: This New Risk Has Been Added
Feb 28
7:59pm ET
Mersana Therapeutics upgraded to Buy from Neutral at Guggenheim
Feb 28
3:55pm ET
Mersana Therapeutics upgraded to Buy from Neutral at BTIG
Feb 28
12:55pm ET
TD Cowen Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Feb 28
7:22am ET
Mersana Therapeutics Shares Corporate Presentation Update
Feb 28
7:11am ET
Mersana Therapeutics reports Q4 EPS (16c), consensus (16c)
Jan 12
11:36am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 09
1:07am ET
Mersana Therapeutics: A Cautious Hold Amid Clinical and Strategic Uncertainties
Jan 07
5:31am ET
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), GeneDx Holdings (WGS) and Mersana Therapeutics (MRSN)
Jan 05
8:17am ET
Mersana Therapeutics announces business updates, expected 2024 milestones
Jan 02
9:34am ET
BTIG Sticks to Their Hold Rating for Mersana Therapeutics (MRSN)
Dec 31
5:21am ET
BTIG Remains a Hold on Mersana Therapeutics (MRSN)
No recent press releases are available for MRSN
MRSN Financials
Key terms
Ad Feedback
MRSN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRSN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range